PharmaCyte Biotech (PMCB) Return on Capital Employed (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Return on Capital Employed for 15 consecutive years, with 0.08% as the latest value for Q3 2025.
- On a quarterly basis, Return on Capital Employed fell 10.0% to 0.08% in Q3 2025 year-over-year; TTM through Jul 2025 was 0.08%, a 10.0% decrease, with the full-year FY2025 number at 0.08%, down 8.0% from a year prior.
- Return on Capital Employed was 0.08% for Q3 2025 at PharmaCyte Biotech, up from 0.09% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.04% in Q1 2025 to a low of 0.62% in Q3 2021.
- A 5-year average of 0.13% and a median of 0.08% in 2023 define the central range for Return on Capital Employed.
- Peak YoY movement for Return on Capital Employed: soared 56bps in 2021, then dropped -10bps in 2025.
- PharmaCyte Biotech's Return on Capital Employed stood at 0.08% in 2021, then grew by 2bps to 0.08% in 2022, then decreased by -5bps to 0.08% in 2023, then surged by 125bps to 0.02% in 2024, then plummeted by -495bps to 0.08% in 2025.
- Per Business Quant, the three most recent readings for PMCB's Return on Capital Employed are 0.08% (Q3 2025), 0.09% (Q2 2025), and 0.04% (Q1 2025).